Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple Myeloma
The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.
“We do have some interesting correlative results from these patients, as they've gone through sequential therapies, that are quite eye popping and surprising even to scientists and immunologists alike at our institution. We also have a concurrent publication that should be coming out soon on what happens after CAR T progression and this is another important topic, especially as we have 2 approvedCAR Ts that are being used now in the US.”
New research out of Mount Sinai’s Tisch Cancer Institute published in Blood Advances has revealed that sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies, after relapsing on bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma.
CGTLive spoke with Samir Parekh, MD, the director of translational research at the institute, to learn more about the surprising findings of the new study, including the preserved efficacy of secondary T-cell redirection therapies further down the line and not just as a next-line therapy. He discussed the relevance of the research as more CAR T-cell therapies are approved and come to the market.
REFERENCE
Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
